| Mar
1995 |
Established as Jiangsu Cuccess Pharmaceutical
Co., Ltd. and pioneered the “General Dealership”
model in China’s pharmaceutical industry |
| Mar 2001 |
Acquired Hainan Simcere Pharmaceutical Co., Ltd., providing
our company with drug manufacturing capabilities |
| Feb 2003 |
Acquired Nanjing Simcere Dongyuan Pharmaceutical Co.,
Ltd., further strengthening our product portfolio and
production capabilities |
| Jan 2004 |
Established Jiangsu Simcere Pharmaceutical Research
and Development Co., Ltd., providing our company a significant
research and development platform |
| Sep 2005 |
Hony Capital Ltd., a subsidiary of Legend Holdings,
completed it’s strategic investment in Simcere |
| May 2006 |
Simcere acquired 80% of Shandong Simcere Medgenn for
RMB200 million and launched its patented anti-cancer drug,
Endu (also known as "'Endostar") |
| April 2007 |
Simcere sucessfully launched its initial public offering
on the New York Stock Exchange under the ticker symbol
"SCR". This transaction was the first Chinese
Pharmaceutical enterprise listing on NYSE. |
| Oct 2007 |
Simcere completed the acquisition of 51% ownership in
Boda Pharmaceutical and captured 100% of the fast-growing
injectable edaravone market. |
| Nov 2007 |
Simcere acquired 85% equity interest in Nanjing Tung
Chit Pharmaceutical and obtained the nedaplatin market
leading chemotherapeutic drug Jiebaishu. |
| Apr 2008 |
Simcere acquired 70% equity interest in Wuhu Zhongren bringing in SinoFuan, a fluorouracil implant used against tumors. |
| May 2008 |
Simcere Pharmaceutical Group announced SFDA approval of first-to-market generic Biapenem injection Anxin. |
| Aug 2008 |
Simcere announced interim report on Endu Phase IV clinical studies. |
